

Drugs with ACB Score of 1

Generic Name	Brand Name
Alimemazine	Theralen™
Alverine	Spasmonal™
Alprazolam	Xanax™
Amipirazole	Ability™
Asenapine	Saphris™
Atenolol	Tenormin™
Bupropion	Wellbutrin™, Zyban™
Captopril	Capoten™
Cetirizine	Zyrtec™
Chlorthalidone	Diuril™, Hygroton™
Cimetidine	Tagamet™
Citidinium	Librax™
Clorazepate	Tranxene™
Codeine	Contin™
Colchicine	Colcrys™
Desloratadine	Clarinx™
Diazepam	Valium™
Digoxin	Lanoxin™
Dipyridamole	Persantine™
Disopyramide	Norpace™
Fentanyl	Duragesic™, Actiq™
Furosemide	Lasix™
Fluvoxamine	Luvox™
Haloperidol	Haldol™
Hydralazine	Aprisoling™
Hydrocortisone	Cortef™, Cortaid™
Iloperidone	Fanapt™
Isoorbide	Isordil™, Ismog™
Levocetirizine	Xyzal™
Loperamide	Immodium™, others
Loratadine	Claritin™
Metoprolol	Lopressor™, Toprol™
Morphine	MS Contin™, Avinza™
Nifedipine	Procardia™, Adalat™
Paliperidone	Invega™
Prednisone	Deltasone™, Sterapred™
Quinine	Quinaglute™
Ranitidine	Zantac™
Risperidone	Risperdal™
Theophylline	Theodur™, Uniphyll™
Trazodone	Desyrel™
Triamterene	Dyrenium™
Venlafaxine	Effexor™
Warfarin	Coumadin™

Drugs with ACB Score of 2

Generic Name	Brand Name
Amantadine	Symmetrel™
Belladonna	Multiple
Carbamazepine	Tegretol™
Cyclobenzaprine	Flexeril™
Cyproheptadine	Pericatin™
Loxapine	Loxitane™
Meperidine	Demerol™
Methotrimeprazine	Levoprome™
Molindone	Moban™
Nefopam	Nefogestic™
Oxcarbazepine	Trileptal™
Pimozide	Orap™

Categorical Scoring:

- Possible anticholinergics include those listed with a score of 1; Definite anticholinergics include those listed with a score of 2 or 3

Numerical Scoring:

- Add the score contributed to each selected medication in each scoring category
- Add the number of possible or definite Anticholinergic medications

Notes:

- Each definite anticholinergic may increase the risk of cognitive impairment by 46% over 6 years.³
- For each on point increase in the ACB total score, a decline in MMSE score of 0.33 points over 2 years has been suggested.⁴
- Additionally, each one point increase in the ACB total score has been correlated with a 26% increase in the risk of death.⁴

Drugs with ACB Score of 3

Generic Name	Brand Name
Amitriptyline	Elavil™
Amoxapine	Asendis™
Atropine	Sal-Tropine™
Benzotropine	Cogentin™
Brompheniramine	Dimetapp™
Carbinoxamine	Histex™, Carbihist™
Chlorpheniramine	Chlor-Trimeton™
Chlorpromazine	Thorazine™
Clemastine	Tavist™
Clomipramine	Anafanil™
Clozapine	Clozaril™
Darifenacin	Enblex™
Desipramine	Norpramin™
Dicyclomine	Bentyl™
Dimenhydrinate	Dramamine™, others
Diphenhydramine	Benadryl™, others
Doxepin	Sinequan™
Doxylamine	Unisom™, others
Fesoterodine	Toviaz™
Flavoxate	Urispas™
Hydroxyzine	Atarax™, Vistaril™
Hyoscyamine	Anaspaz™, Levsin™
Imipramine	Tofranil™
Meclizine	Antivert™
Methocarbamol	Robaxin™
Nortriptyline	Pamelor™
Olanzapine	Zyprexa™
Orphenadrine	Norflex™
Oxybutynin	Ditropan™
Paroxetine	Paxil™
Perphenazine	Trilafon™
Promethazine	Phenegan™
Propanteline	Pro-Banthine™
Quetiapine	Detrunorm™
Scopolamine	Seroquel™
Scopolamine	Transderm Scop™
Sulfenacin	Vasicare™
Thioridazine	Mellaril™
Tolterodine	Detrol™
Trifluoperazine	Stelazine™
Trihexyphenidyl	Artane™
Trimipramine	Surmontil™
Trospium	Sanctura™

Aging Brain Care

www.agingbraincare.org

Medications Reviewed in 2012 Update

Medications Added with Score of 1:	Medications Added with Score of 2:
Artiprazole (Ablify™)	Nefopam (Nefogesic™)
Asenapine (Saphris™)	
Cetirizine (Zyrtec™)	
Clidinium (Librax™)	
Desloratadine (Clarinex™)	
Lloperidone (Fanapt™)	
Levocetirizine (Xyzal™)	
Loratadine (Claritin™)	
Paliperidone (Invega™)	
Venlafaxine (Effexor™)	
	Medications Added with Score of 3:
	Doxylamine (Unisom™, others)
	Fesoterodine (Toviaz™)
	Propiverine (Detrunorm™)
	Solfenacin (Vesicare™)
	Trospium (Sanctura™)

Medications Reviewed But NOT Added:
Fexofenadine (Allegra™)
Gabapentin (Neurontin™)
Topiramate (Topamax™)
Levetiracetam (Keppra™)
Tamoxifen (Nolvadex™)
Nizatidine (Axid™)
Duloxetine (Cymbalta™)

Criteria for Categorization:

- Score of 1: Evidence from in vitro data that chemical entity has antagonist activity at muscarinic receptor.
- Score of 2: Evidence from literature, prescriber's information, or expert opinion of clinical anticholinergic effect.
- Score of 3: Evidence from literature, expert opinion, or prescribers information that medication may cause delirium.

Complete References:

- Boustani MA, Campbell NL, Munger S, Maidment I, Fox GC. Impact of anticholinergics on the aging brain: a review and practical application. *Aging Health*. 2008;4(3):311-320.
- Campbell N, Boustani M, Limbil T, et al. The cognitive impact of anticholinergics: a clinical review. *Clinical Interventions in Aging*. 2009;4(1):225-233.
- Campbell N, Boustani M, Lanek, et al. Use of anticholinergics and the risk of cognitive impairment in an African-American population. *Neurology*. 2010;75:152-159.
- Fox C, Richardson K, Maidment I, et al. Anticholinergic medication use and cognitive impairment in the older population: the Medical Research Council Cognitive Function and Ageing Study. *Journal of the American Geriatric Society*. 2011; 59(8): 1477-1483.
- Cai X, Campbell N, Khan B, Callahan C, Boustani M. Long-term anticholinergic use and the aging brain. *Alzheimers Dementia*. 2012; epub ahead of print.

Copyright © 2008, 2012. Regenstrief Institute, Inc. All rights reserved.

Use of the Anti-Cholinergic Burden (ACB) Scale may only be in accordance with the Terms of Use for the ACB Scale which are available at <http://www.agingbraincare.org/tools/lab-anticholinergic-cognitive-burden-scale>.

To request permission for use, contact us at acb@agingbraincare.org.

Aging Brain Care

**ANTICHOLINERGIC
COGNITIVE BURDEN
SCALE**

2012 Update

Developed by the Aging Brain Program
of the Indiana University Center for
Aging Research

